Cargando…

Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma

Metastatic clear cell renal cell carcinoma (mccRCC) benefits from several treatment options in the first-line setting with VEGFR inhibitors and/or immunotherapy including anti-PD-L1 or anti-PD1 agents. Identification of predictive biomarkers is highly needed to optimize patient care. Circulating mar...

Descripción completa

Detalles Bibliográficos
Autores principales: Montemagno, Christopher, Hagege, Anais, Borchiellini, Delphine, Thamphya, Brice, Rastoin, Olivia, Ambrosetti, Damien, Iovanna, Juan, Rioux-Leclercq, Nathalie, Porta, Camillio, Negrier, Sylvie, Ferrero, Jean-Marc, Chamorey, Emmanuel, Pagès, Gilles, Dufies, Maeva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714499/
https://www.ncbi.nlm.nih.gov/pubmed/33299657
http://dx.doi.org/10.1080/2162402X.2020.1846901
_version_ 1783618759965016064
author Montemagno, Christopher
Hagege, Anais
Borchiellini, Delphine
Thamphya, Brice
Rastoin, Olivia
Ambrosetti, Damien
Iovanna, Juan
Rioux-Leclercq, Nathalie
Porta, Camillio
Negrier, Sylvie
Ferrero, Jean-Marc
Chamorey, Emmanuel
Pagès, Gilles
Dufies, Maeva
author_facet Montemagno, Christopher
Hagege, Anais
Borchiellini, Delphine
Thamphya, Brice
Rastoin, Olivia
Ambrosetti, Damien
Iovanna, Juan
Rioux-Leclercq, Nathalie
Porta, Camillio
Negrier, Sylvie
Ferrero, Jean-Marc
Chamorey, Emmanuel
Pagès, Gilles
Dufies, Maeva
author_sort Montemagno, Christopher
collection PubMed
description Metastatic clear cell renal cell carcinoma (mccRCC) benefits from several treatment options in the first-line setting with VEGFR inhibitors and/or immunotherapy including anti-PD-L1 or anti-PD1 agents. Identification of predictive biomarkers is highly needed to optimize patient care. Circulating markers could reflect the biology of metastatic disease. Therefore, we evaluated soluble forms of PD-L1 (sPD-L1) and PD-1 (sPD-1) in mccRCC patients. The levels of sPD-L1 and sPD-1 were evaluated from plasma samples of mccRCC patients before they received a first-line treatment (T0) by the VEGFR inhibitor sunitinib (50 patients) or by the anti-VEGF bevacizumab (37 patients). The levels of sPD-L1 and sPD-1 were correlated to clinical parameters and progression-free survival (PFS). High levels of sPD-1 or sPDL1 were not correlated to PFS under bevacizumab while they were independent prognostic factors of PFS in the sunitinib group. Patients with high T0 plasmatic levels of sPD-L1 had a shorter PFS (11.3 vs 22.5 months, p = .011) in the sunitinib group. Equivalent shorter PFS was found with high levels of sPD-1 (8.6 vs 14.1 months, p = .009). mccRCC patients with high plasmatic levels of sPD-L1 or sPD-1 are poor responders to sunitinib. sPD-L1 or sPD-1 could be a valuable tool to guide the optimal treatment strategy including VEGFR inhibitor.
format Online
Article
Text
id pubmed-7714499
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-77144992020-12-08 Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma Montemagno, Christopher Hagege, Anais Borchiellini, Delphine Thamphya, Brice Rastoin, Olivia Ambrosetti, Damien Iovanna, Juan Rioux-Leclercq, Nathalie Porta, Camillio Negrier, Sylvie Ferrero, Jean-Marc Chamorey, Emmanuel Pagès, Gilles Dufies, Maeva Oncoimmunology Original Research Metastatic clear cell renal cell carcinoma (mccRCC) benefits from several treatment options in the first-line setting with VEGFR inhibitors and/or immunotherapy including anti-PD-L1 or anti-PD1 agents. Identification of predictive biomarkers is highly needed to optimize patient care. Circulating markers could reflect the biology of metastatic disease. Therefore, we evaluated soluble forms of PD-L1 (sPD-L1) and PD-1 (sPD-1) in mccRCC patients. The levels of sPD-L1 and sPD-1 were evaluated from plasma samples of mccRCC patients before they received a first-line treatment (T0) by the VEGFR inhibitor sunitinib (50 patients) or by the anti-VEGF bevacizumab (37 patients). The levels of sPD-L1 and sPD-1 were correlated to clinical parameters and progression-free survival (PFS). High levels of sPD-1 or sPDL1 were not correlated to PFS under bevacizumab while they were independent prognostic factors of PFS in the sunitinib group. Patients with high T0 plasmatic levels of sPD-L1 had a shorter PFS (11.3 vs 22.5 months, p = .011) in the sunitinib group. Equivalent shorter PFS was found with high levels of sPD-1 (8.6 vs 14.1 months, p = .009). mccRCC patients with high plasmatic levels of sPD-L1 or sPD-1 are poor responders to sunitinib. sPD-L1 or sPD-1 could be a valuable tool to guide the optimal treatment strategy including VEGFR inhibitor. Taylor & Francis 2020-11-25 /pmc/articles/PMC7714499/ /pubmed/33299657 http://dx.doi.org/10.1080/2162402X.2020.1846901 Text en © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Montemagno, Christopher
Hagege, Anais
Borchiellini, Delphine
Thamphya, Brice
Rastoin, Olivia
Ambrosetti, Damien
Iovanna, Juan
Rioux-Leclercq, Nathalie
Porta, Camillio
Negrier, Sylvie
Ferrero, Jean-Marc
Chamorey, Emmanuel
Pagès, Gilles
Dufies, Maeva
Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma
title Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma
title_full Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma
title_fullStr Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma
title_full_unstemmed Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma
title_short Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma
title_sort soluble forms of pd-l1 and pd-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714499/
https://www.ncbi.nlm.nih.gov/pubmed/33299657
http://dx.doi.org/10.1080/2162402X.2020.1846901
work_keys_str_mv AT montemagnochristopher solubleformsofpdl1andpd1asprognosticandpredictivemarkersofsunitinibefficacyinpatientswithmetastaticclearcellrenalcellcarcinoma
AT hagegeanais solubleformsofpdl1andpd1asprognosticandpredictivemarkersofsunitinibefficacyinpatientswithmetastaticclearcellrenalcellcarcinoma
AT borchiellinidelphine solubleformsofpdl1andpd1asprognosticandpredictivemarkersofsunitinibefficacyinpatientswithmetastaticclearcellrenalcellcarcinoma
AT thamphyabrice solubleformsofpdl1andpd1asprognosticandpredictivemarkersofsunitinibefficacyinpatientswithmetastaticclearcellrenalcellcarcinoma
AT rastoinolivia solubleformsofpdl1andpd1asprognosticandpredictivemarkersofsunitinibefficacyinpatientswithmetastaticclearcellrenalcellcarcinoma
AT ambrosettidamien solubleformsofpdl1andpd1asprognosticandpredictivemarkersofsunitinibefficacyinpatientswithmetastaticclearcellrenalcellcarcinoma
AT iovannajuan solubleformsofpdl1andpd1asprognosticandpredictivemarkersofsunitinibefficacyinpatientswithmetastaticclearcellrenalcellcarcinoma
AT riouxleclercqnathalie solubleformsofpdl1andpd1asprognosticandpredictivemarkersofsunitinibefficacyinpatientswithmetastaticclearcellrenalcellcarcinoma
AT portacamillio solubleformsofpdl1andpd1asprognosticandpredictivemarkersofsunitinibefficacyinpatientswithmetastaticclearcellrenalcellcarcinoma
AT negriersylvie solubleformsofpdl1andpd1asprognosticandpredictivemarkersofsunitinibefficacyinpatientswithmetastaticclearcellrenalcellcarcinoma
AT ferrerojeanmarc solubleformsofpdl1andpd1asprognosticandpredictivemarkersofsunitinibefficacyinpatientswithmetastaticclearcellrenalcellcarcinoma
AT chamoreyemmanuel solubleformsofpdl1andpd1asprognosticandpredictivemarkersofsunitinibefficacyinpatientswithmetastaticclearcellrenalcellcarcinoma
AT pagesgilles solubleformsofpdl1andpd1asprognosticandpredictivemarkersofsunitinibefficacyinpatientswithmetastaticclearcellrenalcellcarcinoma
AT dufiesmaeva solubleformsofpdl1andpd1asprognosticandpredictivemarkersofsunitinibefficacyinpatientswithmetastaticclearcellrenalcellcarcinoma